PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
STW 1 (a combination extract containing S. virgaurea) demonstrated anti-inflammatory, analgesic, and antioxidative properties, reducing the intake of non-steroidal anti-inflammatory drugs (NSAIDs) [PMID:17704984].
In alloxan-induced diabetic rats, S. virgaurea extract significantly reduced blood glucose, serum amylase activity, and TNF-α levels, while increasing serum insulin and liver glycogen [PMID:32026741].
S. virgaurea extracts and essential oils showed antimicrobial activity against Gram-positive microorganisms [PMID:39204623] and moderate antibacterial activity against Staphylococcus aureus [PMID:19857881]. Water extracts inhibited the yeast-hyphal transition and biofilm formation of Candida albicans [PMID:22422572].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 33266185 (2020) — Solidago virgaurea L.: A Review of Its Ethnomedicinal Uses, Phytochemistry, and Pharmacological Activities. · Biomolecules
- 2.PMID: 37900701 (2023) — In Vitro and In Vivo Evaluation of the Antidiabetic Activity of Solidago virgaurea Extracts. · Current bioactive compounds
- 3.PMID: 28543097 (2017) — Contact dermatitis as an adverse reaction to some topically used European herbal medicinal products - part 4: Solidago virgaurea-Vitis vinifera. · Contact dermatitis
- 4.PMID: 30609133 (2019) — Flavonoids enantiomer distribution in different parts of goldenrod (Solidago virgaurea L.), lucerne (Medicago sativa L.) and phacelia (Phacelia tanacetifolia Benth.). · Chirality
- 5.PMID: 32026741 (2022)